271 related articles for article (PubMed ID: 35887001)
1. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.
Lee J; Kim JS; Cho HI; Jo SR; Jang YK
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001
[TBL] [Abstract][Full Text] [Related]
2. JIB-04, A Small Molecule Histone Demethylase Inhibitor, Selectively Targets Colorectal Cancer Stem Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway.
Kim MS; Cho HI; Yoon HJ; Ahn YH; Park EJ; Jin YH; Jang YK
Sci Rep; 2018 Apr; 8(1):6611. PubMed ID: 29700375
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
4. JIB-04, a histone demethylase Jumonji C domain inhibitor, regulates phenotypic switching of vascular smooth muscle cells.
He Y; Yi X; Zhang Z; Luo H; Li R; Feng X; Fang ZM; Zhu XH; Cheng W; Jiang DS; Zhao F; Wei X
Clin Epigenetics; 2022 Aug; 14(1):101. PubMed ID: 35964071
[TBL] [Abstract][Full Text] [Related]
5. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M
Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
Kahraman DC; Kahraman T; Cetin-Atalay R
Mol Cancer Ther; 2019 Nov; 18(11):2146-2157. PubMed ID: 31439713
[TBL] [Abstract][Full Text] [Related]
8. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
Wang L; Chang J; Varghese D; Dellinger M; Kumar S; Best AM; Ruiz J; Bruick R; Peña-Llopis S; Xu J; Babinski DJ; Frantz DE; Brekken RA; Quinn AM; Simeonov A; Easmon J; Martinez ED
Nat Commun; 2013; 4():2035. PubMed ID: 23792809
[TBL] [Abstract][Full Text] [Related]
9. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
Liu J; Nie C
Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516
[TBL] [Abstract][Full Text] [Related]
10. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
11. Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression.
Deng Y; Li M; Zhuo M; Guo P; Chen Q; Mo P; Li W; Yu C
J Biol Chem; 2021; 296():100121. PubMed ID: 33434575
[TBL] [Abstract][Full Text] [Related]
12. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
14. Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway.
Zhang XL; Jia Q; Lv L; Deng T; Gao J
Anticancer Agents Med Chem; 2015; 15(6):755-63. PubMed ID: 25642979
[TBL] [Abstract][Full Text] [Related]
15. Jumonji Histone Demethylase Inhibitor JIB-04 as a Broad-Spectrum Antifungal Agent.
Wang T; Yang W; Liu Y; Li W; Wang Y; Liu N; Sheng C
ACS Infect Dis; 2022 Jul; 8(7):1316-1323. PubMed ID: 35695031
[TBL] [Abstract][Full Text] [Related]
16. Connexin32 regulates expansion of liver cancer stem cells via the PI3K/Akt signaling pathway.
Li H; Wang B; Qi B; Jiang G; Qin M; Yu M
Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35894130
[TBL] [Abstract][Full Text] [Related]
17. KDM6B Counteracts EZH2-Mediated Suppression of
Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract][Full Text] [Related]
19. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
20. Disruption of the
Matthews KA; Senagbe KM; Nötzel C; Gonzales CA; Tong X; Rijo-Ferreira F; Bhanu NV; Miguel-Blanco C; Lafuente-Monasterio MJ; Garcia BA; Kafsack BFC; Martinez ED
ACS Infect Dis; 2020 May; 6(5):1058-1075. PubMed ID: 32272012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
